Purchase Order 75N95024P00096
Award Date
2/2/24
Potential Completion Date
2/1/25
Potential Value
$101K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Reaction Biology Corporation
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $110,000.00 firm fixed price purchase order to Reaction Biology Corporation, a self-certified small disadvantaged business, for the testing of compounds to inhibit wild-type kinase enzymes. This requirement does not have a set-aside designation. Reaction Biology Corporation is a contract research organization that provides specialized bioassay testing and...
Reaction Biology Corporation was awarded a $109,470 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health's National Institute on Drug Abuse to provide compound testing services in support of kinase enzyme inhibition and cardiac ion channel block research. As the prime contractor, Reaction Biology will test 330 small molecule compounds using its Kinase HotSpot and automated patch-clamp assay platforms to characterize inhibition of kinase...
This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...
This is a firm-fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation. The $80,000.00 contract is for the provision of specialized preclinical services, including enzyme activity assays, screening, and related laboratory services to support biomedical research initiatives. Reaction Biology, a self-certified small disadvantaged business, has primarily...
This is a $35,817.60 firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for methyltransferase panel screening using Reaction Biology's proprietary Methyltransferase HotSpot assay platform to support NCATS' Early Translation Branch (ETB) and the DPI_SARS-CoV-2_Variant Trace project. This non-competitive award...
This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $18,028.80 to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract, which does not have a set-aside designation, was awarded on June 5, 2019, with a completion date of December 13, 2019. Reaction Biology Corporation, a drug discovery contract research organization,...